Traws Pharma, Inc. (TRAW)
NASDAQ: TRAW · Real-Time Price · USD
1.210
+0.070 (6.14%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Traws Pharma Employees
As of December 31, 2024, Traws Pharma had 7 total employees, including 6 full-time and 1 part-time employees. The number of employees decreased by 11 or -61.11% compared to the previous year.
Employees
7
Change (1Y)
-11
Growth (1Y)
-61.11%
Revenue / Employee
$398,571
Profits / Employee
$980,714
Market Cap
12.29M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Lunai Bioworks | 29 |
| BioCardia | 21 |
| Moleculin Biotech | 17 |
| Reviva Pharmaceuticals Holdings | 14 |
| BioVie | 13 |
| Cellectar Biosciences | 11 |
| Intensity Therapeutics | 7 |
| Jupiter Neurosciences | 5 |
TRAW News
- 13 days ago - Traws Pharma Earnings Call Transcript: Q4 2025 - Transcripts
- 13 days ago - Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights - GlobeNewsWire
- 2 months ago - Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza - GlobeNewsWire
- 3 months ago - Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients - GlobeNewsWire
- 6 months ago - ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials - PRNewsWire
- 6 months ago - Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19. - PRNewsWire
- 7 months ago - Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025 - GlobeNewsWire
- 9 months ago - Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025 - GlobeNewsWire